MUC16 Specific Neutra™ Antibody Products
Product listMucin 16 (MUC16) belongs to the mucin protein family. Mucins are large, O-glycosylated molecules crucial for creating a protective mucosal layer, primarily found on the apical surfaces of epithelial cells. This protein plays a critical role in forming a protective barrier that shields epithelial cells from pathogens. Variants of this gene have been utilized as biomarkers in various cancers, with elevated expression levels correlating with poorer prognoses. Diseases linked to MUC16 include clear cell adenocarcinoma and serous cystadenocarcinoma. It is involved in pathways related to protein metabolism.
Its Gene ID: 94025, UniProtKB ID: Q8WXI7, and OMIM ID: 606154.
MUC16 Signaling Pathway in Cancer
Widely employed in clinical settings, MUC16 serves as a screening tool for early-stage breast cancer diagnosis and prognosis. Expression of MUC16 enhances tumor cell proliferation through its interaction with non-receptor tyrosine kinase JAK2, resulting in STAT3 phosphorylation and subsequent induction of Cyclin D1 and c-Jun expression. MUC16 also influences the G2/M transition through Cyclin B1 and Aurora kinase A phosphorylation. Reduced MUC16 expression results in the accumulation of malignant cells during the G2/M phase of the cell cycle, leading to apoptosis via JNK signaling in breast cancer cells.
Fig.1 The·expression of MUC16 in cancer.1, 2
MUC16 Antibodies Applications
- Anti-MUC16 Antibody in Cancer Therapeutic Research
MUC16 is a tumor-specific antigen prominently overexpressed in pancreatic and ovarian cancers. A constructed ADC incorporates a humanized anti-MUC16 monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E. Clinical treatment of patients with ovarian and pancreatic cancers using anti-MUC16 ADC drugs has shown an acceptable safety profile and has demonstrated anti-tumor activity in patients with MUC16-expressing tumors. These findings support the potential of anti-MUC16 ADCs in cancer therapy research.
- Bispecific Antibodies Targeting MUC16 Demonstrate Efficacy in Ovarian Cancer Treatment
Immunotherapy research for ovarian cancer is actively pursued. Novel bispecific tandem single-chain variable fragments targeting the conserved segment of human MUC16 ectodomain and human CD3 have been developed. This kind of MUC16 ectodomain-bispecific antibodies maintain binding affinity in the presence of soluble MUC16 and demonstrate cytotoxic effects against various ovarian cancer cell lines in vitro. In vivo studies demonstrate that MUC16 ectodomain bispecific fragments inhibit tumor progression and markedly prolong survival in a xenograft model of ovarian peritoneal carcinomatosis. This therapeutic efficacy is significantly augmented when combined with immune checkpoint inhibition (PD1) and antiangiogenic (VEGF) therapy. Importantly, the combination of bispecific tandem single-chain variable fragments with anti-VEGF shows superior outcomes compared to anti-PD1, evidenced by reduced peritoneal tumor burden and ascites. These findings underscore the potential and effectiveness of MUC16 ectodomain-bispecific tandem single-chain variable fragments, advocating their combination with anti-VEGF therapy as a promising strategy for ovarian cancer treatment.
Creative Biolabs offers an extensive array of over 20 meticulously developed antibodies targeting MUC16, engineered with advanced recombinant techniques. Additionally, customized services are available to design neutralizing antibodies that precisely target MUC16, tailored to meet specific needs.
REFERENCES
- Saad, Hebatallah M., et al. "The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity." Diagnostics 12.12 (2022): 2985.
- Distributed Under open access license CC BY 4.0, without modification.
